NCT00759525View on ClinicalTrials.gov

The Role of Mineralocorticoid Receptors in Vascular Function

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Apparent Mineralocorticoid Excess (AME)
Interventions
DRUG

Glycyrrhetic Acid

130 mg daily for fourteen days

DRUG

Placebo

Placebo daily for fourteen days

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT00759525 - The Role of Mineralocorticoid Receptors in Vascular Function | Biotech Hunter | Biotech Hunter